244 related articles for article (PubMed ID: 23053592)
1. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
Nakanishi T; Kuragano T; Kaibe S; Nagasawa Y; Hasuike Y
Clin Exp Nephrol; 2012 Dec; 16(6):819-26. PubMed ID: 23053592
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
3. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
Ueda N; Takasawa K
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
[TBL] [Abstract][Full Text] [Related]
4. Hepcidin for clinicians.
Young B; Zaritsky J
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1384-7. PubMed ID: 19556376
[TBL] [Abstract][Full Text] [Related]
5. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
[TBL] [Abstract][Full Text] [Related]
6. Iron supplementation to treat anemia in patients with chronic kidney disease.
Besarab A; Coyne DW
Nat Rev Nephrol; 2010 Dec; 6(12):699-710. PubMed ID: 20956992
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin: clinical utility as a diagnostic tool and therapeutic target.
Coyne DW
Kidney Int; 2011 Aug; 80(3):240-4. PubMed ID: 21677632
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
9. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
10. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.
Atkinson MA; White CT
Pediatr Nephrol; 2012 Jan; 27(1):33-40. PubMed ID: 21400189
[TBL] [Abstract][Full Text] [Related]
12. Assessing iron status: beyond serum ferritin and transferrin saturation.
Wish JB
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
14. [Iron, hepcidin and chronic kidney disease].
Fievet P; Brazier F
Nephrol Ther; 2011 Apr; 7(2):86-91. PubMed ID: 21186144
[TBL] [Abstract][Full Text] [Related]
15. Effects of iron supplementation on serum hepcidin and serum erythropoietin in low-birth-weight infants.
Berglund S; Lönnerdal B; Westrup B; Domellöf M
Am J Clin Nutr; 2011 Dec; 94(6):1553-61. PubMed ID: 22071701
[TBL] [Abstract][Full Text] [Related]
16. Hepcidin is a potential regulator of iron status in chronic kidney disease.
Tsuchiya K; Nitta K
Ther Apher Dial; 2013 Feb; 17(1):1-8. PubMed ID: 23379486
[TBL] [Abstract][Full Text] [Related]
17. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
Takasawa K; Takaeda C; Wada T; Ueda N
Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
[No Abstract] [Full Text] [Related]
18. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
[TBL] [Abstract][Full Text] [Related]
19. Serum hepcidin in clinical specimens.
Dallalio G; Fleury T; Means RT
Br J Haematol; 2003 Sep; 122(6):996-1000. PubMed ID: 12956771
[TBL] [Abstract][Full Text] [Related]
20. Association of hepcidin and anemia in early chronic kidney disease.
Sonkar SK; Singh NK; Sonkar GK; Pandey S; Bhosale V; Kumar A; Usman K
Saudi J Kidney Dis Transpl; 2019; 30(2):315-324. PubMed ID: 31031367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
